Portola Pharmaceuticals reports retirement of John Curnutte, head of R&D
Portola Pharmaceuticals announced that Dr. John Curnutte, M.D., Ph.D., Executive Vice President and Head of Research and Development, will retire on May 17 after more than eight years of service. Portola said in a statement: "Dr. Curnutte will remain in a consultancy role, providing guidance to Portola's President and CEO Scott Garland and engaging with key academic and scientific thoughtleaders in the field on the ongoing development of Andexxa and cerdulatinib." Moving forward, and effective May 1, the company's research efforts will be led by Pamela Conley, Ph.D., Senior Vice President of Research. The company expects to name a permanent Chief Medical Officer upon completion of the previously announced executive search. During the transition period, Portola's Vice President of Medical Affairs, Jeff Myers, M.D., Ph.D., will serve as interim Chief Medical Officer.